Supplementary Table S1. Kappa values for intraobserver reliability.

Assessment / Greyscale / Power Doppler / Erosions
Overall / 0.83 / 0.87 / 0.93
PIP / 0.85 / 0.91 / -
MCP / 0.85 / 0.91 / -
Wrist / 0.77 / 0.81 / -
Elbow / 0.81 / 0.82 / -
Shoulder / 0.86 / 0.65 / -
Knee / 0.77 / 0.70 / -
Ankle / 0.77 / 0.75 / -
MTP / 0.76 / 0.88 / -

A kappa value of 0-0.2 was considered poor, 0.21-0.40 fair, 0.41-0.6 moderate, 0.61-0.8 good, and 0.81 to 1 excellent.

Supplementary Table S2.Distribution of clinical and US findings in joint areas by outcome.

VERA / VENRA / Resolving
Clinical joint area involvement, n (%)
PIP swelling / 18 (62) / 5 (39) / 2 (12.5)
MCP swelling / 28 (97) / 6 (46) / 3 (19)
Wrist swelling / 20 (69) / 2 (15) / 2 (12.5)
Elbow swelling / 3 (10) / 1 (8) / 0
Shoulder swelling / 0 / 0 / 0
Knees swelling / 14 (48) / 7 (54) / 7 (44)
Ankles swelling / 8 (28) / 3 (23) / 7 (44)
MTP swelling / 5 (17) / 0 / 0
Clinical joint area symmetry, n (%)
PIP swelling / 12 (41) / 1 (38) / 1 (6)
MCP swelling / 19 (66) / 1 (8) / 0
Wrist swelling / 14 (48) / 1 (8) / 1 (6)
Elbow swelling / 1 (3) / 0 / 0
Shoulder swelling / 0 / 0 / 0
Knees swelling / 7 (24) / 2 (15) / 1 (6)
Ankles swelling / 5 (17) / 0 / 5 (31)
MTP swelling / 3 (10) / 0 / 0
Greyscale joint area involvement, n (%)
PIP / 23 (79) / 8 (62) / 3 (19)
MCP / 29 (100) / 12 (92) / 6 (37.5)
Wrist / 28 (97) / 9 (69) / 9 (50)
Elbow / 13 (45) / 7 (53) / 2 (12.5)
Shoulder / 4 (14) / 2 (15) / 2 (12.5)
Knees / 25 (86) / 9 (69) / 11 (69)
Ankles / 20 (69) / 5 (38) / 10 (62.5)
MTP / 20 (69) / 7 (54) / 6 (37.5)
Greyscalejoint area symmetry, n (%)
PIP / 14 (48) / 5 (38) / 1 (6)
MCP / 27 (93) / 5 (38) / 2 (12.5)
Wrist / 25 (86) / 6 (46) / 5 (31)
Elbow / 7 (24) / 2 (15) / 1 (6)
Shoulder / 2 (7) / 2 (15) / 0
Knees / 15 (52) / 8 (62) / 7 (44)
Ankles / 10 (34) / 2 (15) / 4 (25)
MTP / 16 (55) / 4 (31) / 2 (12.5)
Power doppler joint area involvement, n (%)
PIP / 22 (76) / 8 (62) / 1 (6)
MCP / 28 (96) / 9 (69) / 4 (25)
Wrist / 27 (93) / 8 (62) / 9 (56)
Elbow / 11 (38) / 6 (46) / 1 (6)
Shoulder / 1 (3.4) / 0 / 0
Knees / 18 (62) / 4 (31) / 10 (62.5)
Ankles / 15 (52) / 3 (23) / 8 (50)
MTP / 15 (52) / 2 (15) / 1 (6)
Power doppler joint area symmetry, n (%)
PIP / 13 (45) / 2 (15) / 1 (6)
MCP / 24 (83) / 4 (31) / 2 (12.5)
Wrist / 24 (83) / 5 (38) / 5 (31)
Elbow / 5 (17) / 0 / 0
Shoulder / 0 / 0 / 0
Knees / 8 (28) / 1 (8) / 6 (37.5)
Ankles / 8 (28) / 0 / 3 (19)
MTP / 10 (34) / 0 / 0

SupplemtaryTable S3.Final outcome of patients identified by clinical and ultrasound 2010 RA criteria.

Baseline clinical 2010 criteria, n = 26
Final diagnosis by 1987 criteria, n (%)
RA
PsA
SLE
Parvovirus
Pseudogout
Reactive
Septic
Unclassified / VERA
24 (92)
0
0
0
0
0
0
0 / VENRA
0
0
1 (4)
0
0
0
0
1 (4) / resolving
0
0
0
0
0
0
0
0
Baseline USGS 2010 criteria† n = 34
Final diagnosis by 1987 criteria, n (%)
RA
PsA
SLE
Parvovirus
Pseudogout
Reactive
Septic
Unclassified / 27 (79)
0
0
0
0
0
0
0 / 0
0
2 (6)
0
0
0
0
3 (9) / 0
0
0
0
0
0
0
2 (6)
Final clinical 2010 criteria, n= 25*
Final diagnosis by 1987 criteria, n (%)
RA
PsA
SLE
Parvovirus
Pseudogout
Reactive
Septic
Unclassified / 25 (96)
0
0
0
0
0
0
0 / 0
0
0
0
0
0
0
1 (4) / 0
0
0
0
0
0
0
0

† Clinical examination variables have been replaced by ultrasonographic criteria of joint involvement (usgs≥1) and erosion

US: Ultrasound, GS: greyscale ultrasound

*Note that 2 patients developing SLE during follow-up are no longer classified as RA at 18 months according to ACR/EULAR 2010 criteria. Only one more patient is classified as having RA during this time period by 2010 criteria.